Advanced Prostate Cancer COE

Clinical Trials: Another Treatment Option for Patients - Tom Farrington

Tom Farrington and Alicia Morgans discuss how to engage best with patients about clinical trials and clinical care. Tom emphasizes that patients are simply not aware of clinical trials that are available and that these trials present " another treatment option ". Clinical trials that offer randomization to the standard of care or the standard of care plus the additional treatment option being eval...

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines - Oliver Sartor

Oliver Sartor, MD discusses his contributions to the recent publication in JAMA Oncology on the prevalence of germline variants in prostate cancer and the implications for genetic testing guidelines. 3600 patients had various forms of germiline genetic testing performed and were available for this analysis. In the dataset, 17% of patients had germline variants and 30% of those were BRCA1/BRCA2. In...

Biomarkers Across the Spectrum of Prostate Cancer- Anis Hamid and Chris Sweeney

Anis Hamid and Chris Sweeney discuss their recent work studying biomarkers across the full spectrum of prostate cancer. Based on preclinical studies we understand that aggressive disease lies in the tumor genome and we see recurrent losses of certain genes in both early and advanced prostate cancer. The classic tumor suppressors that are commonly mutated across cancers, including prostate cancer,...

Influence of BRCA-2 Mutations on the Natural History and Response to Therapy in Prostate Cancer- Elena Castro

Elena Castro, MD discusses the role of BRCA-2 mutations and the risk of developing prostate cancer. BRCA-2 germline carriers have an increased risk of developing prostate cancer representing a ~30% lifetime rate of developing prostate cancer. Patients with BRCA-2 mutations tend to develop more aggressive prostate cancer and typically present with lymph node involvement or distant metastases. Based...

Integrating Genomics into Localized Prostate Cancer - Todd Morgan and Dan Spratt

Dan Spratt and Todd Morgan discuss the role of genomics in localized prostate cancer from the perspective of the radiation oncologist and the urologist. Based on the MUSIC registry, which represents over 90% of the urology practices across Michigan, they reveal that most of the prostate cancer patients are not receiving genomic profiling. Drs. Spratt and Morgan review each of the genomic tests inc...

Use of MRI to Risk Stratify Patients with Prostate Cancer- Simpa Salami

Simpa Salami, MD discusses the role of MRI in risk stratifying patients with prostate cancer. MRI has revolutionized the ability to detect aggressive prostate cancer but it is still possible that patients who have a negative MRI still have aggressive cancer. Up to 10-15% of patients may have aggressive prostate cancer despite negative findings on MRI. Dr. Salami addresses why these patients may ha...

Disruptive Technologies in Radiology & Nuclear Medicine - Phillip Koo

Phillip Koo and Alicia Morgans discuss disruptive changes impacting clinical practice. Clearly, medical practice disruptions occur more incrementally than when we think of what this means in consumer-based areas and yet each day new data from key clinical trials has the potential to shake up what is viewed-as the current standard of care. New data is challenging radiology and nuclear medicine as w...

Challenges in the Treatment of Localized Prostate Cancer - Srikala Sridhar

Kala Sridhar and Alicia Morgans share in a discussion on challenges and opportunities in the treatment of localized prostate cancer from the viewpoint of a medical oncologist. Conversation includes approaches for optimizing systemic therapy in localized disease and new hormonal agents, and the ICECAP initiative. Biographies: Srikala (Kala) Sridhar MD, MSc, FRCPC Medical Advisory and Research Board...

Diagnostic Performance of 68Ga PSMA PET CT to Detect Significant Prostate Cancer and Comparison with 18F Choline PET CT - Manuela Hoffmann

Radiolabeled prostate-specific membrane antigen (PSMA) has proven as a highly accurate method to detect recurrences and metastases of prostate cancer, but there are only sparse data about its diagnostic performance in primary prostate cancer. Manuela Hoffman presents a retrospective study of the diagnostic performance of 68Ga-PSMA PET/CT to detect significant prostate cancer in comparison with 18F...

Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus ADT for Men with Advanced Prostate Cancer - Tom Keane

(Length of video: 9 min) Tom Keane reviews an article entitled, “Comparative Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus Androgen Deprivation Therapy for Men with Advanced Prostate Cancer”. Men with locally advanced prostate cancer or regionally advanced prostate cancer treated initially with radical prostatectomy plus radiation had a lower risk of pr...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.